Pfizer Faces Setbacks with Clinical Trial Failure and CFO Departure
Pfizer (PFE) has experienced a significant decline in stock value since late 2021 due to poor financial results. Recent setbacks include the failure of sigvotatug vedotin, an investigational drug for non-small cell lung cancer acquired through its $43 billion purchase of Seagen, and the departure of CFO Dave Denton.
Tickers: $PFE
Topics: leadership change NSCLC clinical trial failure Pfizer Seagen acquisition sigvotatug vedotin